LongCovid
Preliminary data recently published by Nature suggests that taking antiviral ensitrelvir, which is not approved in the United States, shortens symptoms in people with mild COVID and might reduce risk of Long COVID — but more data are needed.
COVID pill is first to cut short positive-test time after infection (nature.com)
A new report on vaccination prevention of Long COVID across multiple cohorts & countries (the UK, Spain and Estonia) found very consistent protection (16-45% reduction), particularly in young people. This preprint article…
As shown by this Science article, research suggests that the risk of Long COVID symptoms 3 months after infection has dropped: Original strain and Alpha: 46%, Delta: 35%…
In this prospective observational cohort study carried out by Charité – Universitätsmedizin Berlin, symptom severity and various biomarkers were evaluated in 106 patients with Post-COVID-19 syndrome (PCS) with moderate to…
A new prospective cohort study published by Nature Medicine (Nature Portfolio) on Long COVID. From more than 1,800 adults hospitalized with Covid-19, the authors identified two distinct biomarker profiles…